Login to Your Account

Clinic roundup

Tuesday, February 18, 2014
Sanbio Inc., of Mountain View, Calif., presented safety and efficacy data from its ongoing phase I/IIa trial of SB623 cell therapy in patients with chronic stroke disability at the International Stroke Conference in San Diego.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription